Mongolian Journal of Health Sciences, 2006, 2(3)
Interferon alpha 2 a and thymus factor treatment Of adults with chronic hepatitis c and its impaction On lymphocytes subpopulation
( Судалгааны өгүүлэл )
School of Public Health, Health Sciences University 2School of Public Health, Health Sciences University 'School of Medicine, Health Sciences University
Өгүүллийн PDF-ийг татах
Абстракт
Chronic HCV infection results in the induction of a strong humoral immune response. We recently described study of impaction on lymphocytes subpopulation during interferon treatment. Aim was to evaluate effect of the interferon alpha 2a and thymus factor combination treatment in adults with chronic hepatitis C and its impact on blood lymphocytes subpopulation. Study period is a one year and involved 36 patients with chronic hepatitis C.
Ном зүй
1. Hoofnagle J.H. Hepatitis C. 1997. The clinical spectrum of disease. Hepatology: 26: (suppl 1) 15S
2. Maier K. Zapalenie 1998. Waiioby, PZWL. Warsaw
3. Seeff L.B, Buskell-Bales Z, Wright E.C. Durako S.J, Alter H.J, Lber F.L, Hollinger F.B, Gitnick G, Knodell R.G, Perrillo R.P. 1992. Long term mortality after
transfusion-associated non-A, non-B hepatitis. N.EngU.Med: 327; p. 1906
4. Takahashi M, Yamada Q Miyamoto R, Doi T, Endo H, Tsuji T. 1993. Natural course of chronic hepatitis C. Am. J. Gastroenterol: 88; p.240
5. Kojima H, Hongo Y, Harada H, Inoure T, Miyaji K, Kashiwagi M, Momose T, Arisaka Y, Fukui H, Murai S, Toita H, Kamitsukasa H, Yagura M, Katsu. 2001. Long-
term histological prognosis and serum fibrosis markers in chronic hepatitis C patients treated with interferon. J Gastroenterol.Hepatol: 16(9); p.1015
6. Sena M.A, Ferrandez A, Gilabert M.S, Rodriguez F, Escudero A, Del Olmo J.A, Compan A, Rodrigo J.M. 1998. Influence of pretreatment lesions on
histologic response to interferon therapy in chronic hepatitis C. JClin.Gastroenterol: 26(4); p.296
7. Schiffmann K.E., Sjogren M., Creager R.L., Ishak K.G, et al, 1998. Combination therapy with thymsin alpha 1 interferon treatment of chronic hepatitis C
infection : A randomized placebo controlled double blind trial. Hepatology. 27/1128/
8. Alric L., Partensky J., Reynard D., Rauzy O., Duffaut M, 2000. Association between polymyositis and hepatitis C infection.treatment realated difficulties.
Rev. Med. Intern., 21(6), p.542
9. Cacoub P. Musset L, Hausfater P, Ghillani P, fabiani F.L, Charlotte F, Angevin E, Opolon P, Poynard T, Piette J.C, Autran B. 1998. No evidence for abnormal
immune activation in peripheral blood T cells in patients with hepatitis C virus (HCV) infection with or without cryoglobulinaemia. Clin.Exp.Immunol: 113(1);
p.48
10. Chan T.M, Ho S.K.N. Lai C.L, Cheng I.K.P, Lai K.N. 1999. Lymphocyte subsets in renal allograft recipients with chronic hepatitis C virus infection.
Nephrol.Dial.Transplant: 14; p.717
16 Davaa et al. Interferon alpha 2a and thymus factor treatment
11. Prince H.E, Fang C.T. 1992. Unaltered lymphocyte subsets in hepatitis C virus seropositive blood donors. Transfusion: 32(2); p. 166
12. Schupper H, Hayashi P, Scheffel J, Aceituno S, Paglieroni T, Holland P.V. 1993. Peripheral blood mononuclear cell responses to recombinant hepatitis C
virus antigens in patients with chronic hepatitis C. Hepatology: 18(5); p. 1055
13. Jirillo E., Greco B., et al. 1996. Immunological effects following administration of interferon alpha in patients with chronic hepatitis C. I
Immunnopharmacology - Immunotoxicology ., 18(3).p.355
14. Kanto T., Hayashi N., Takehara T et al, 1999. Impaired allostimulatory capacity of peripheral blood dendric cells recovered from hepatitis C virus-infected
individuals. J Immunol; 162:55.pp.84-91
2. Maier K. Zapalenie 1998. Waiioby, PZWL. Warsaw
3. Seeff L.B, Buskell-Bales Z, Wright E.C. Durako S.J, Alter H.J, Lber F.L, Hollinger F.B, Gitnick G, Knodell R.G, Perrillo R.P. 1992. Long term mortality after
transfusion-associated non-A, non-B hepatitis. N.EngU.Med: 327; p. 1906
4. Takahashi M, Yamada Q Miyamoto R, Doi T, Endo H, Tsuji T. 1993. Natural course of chronic hepatitis C. Am. J. Gastroenterol: 88; p.240
5. Kojima H, Hongo Y, Harada H, Inoure T, Miyaji K, Kashiwagi M, Momose T, Arisaka Y, Fukui H, Murai S, Toita H, Kamitsukasa H, Yagura M, Katsu. 2001. Long-
term histological prognosis and serum fibrosis markers in chronic hepatitis C patients treated with interferon. J Gastroenterol.Hepatol: 16(9); p.1015
6. Sena M.A, Ferrandez A, Gilabert M.S, Rodriguez F, Escudero A, Del Olmo J.A, Compan A, Rodrigo J.M. 1998. Influence of pretreatment lesions on
histologic response to interferon therapy in chronic hepatitis C. JClin.Gastroenterol: 26(4); p.296
7. Schiffmann K.E., Sjogren M., Creager R.L., Ishak K.G, et al, 1998. Combination therapy with thymsin alpha 1 interferon treatment of chronic hepatitis C
infection : A randomized placebo controlled double blind trial. Hepatology. 27/1128/
8. Alric L., Partensky J., Reynard D., Rauzy O., Duffaut M, 2000. Association between polymyositis and hepatitis C infection.treatment realated difficulties.
Rev. Med. Intern., 21(6), p.542
9. Cacoub P. Musset L, Hausfater P, Ghillani P, fabiani F.L, Charlotte F, Angevin E, Opolon P, Poynard T, Piette J.C, Autran B. 1998. No evidence for abnormal
immune activation in peripheral blood T cells in patients with hepatitis C virus (HCV) infection with or without cryoglobulinaemia. Clin.Exp.Immunol: 113(1);
p.48
10. Chan T.M, Ho S.K.N. Lai C.L, Cheng I.K.P, Lai K.N. 1999. Lymphocyte subsets in renal allograft recipients with chronic hepatitis C virus infection.
Nephrol.Dial.Transplant: 14; p.717
16 Davaa et al. Interferon alpha 2a and thymus factor treatment
11. Prince H.E, Fang C.T. 1992. Unaltered lymphocyte subsets in hepatitis C virus seropositive blood donors. Transfusion: 32(2); p. 166
12. Schupper H, Hayashi P, Scheffel J, Aceituno S, Paglieroni T, Holland P.V. 1993. Peripheral blood mononuclear cell responses to recombinant hepatitis C
virus antigens in patients with chronic hepatitis C. Hepatology: 18(5); p. 1055
13. Jirillo E., Greco B., et al. 1996. Immunological effects following administration of interferon alpha in patients with chronic hepatitis C. I
Immunnopharmacology - Immunotoxicology ., 18(3).p.355
14. Kanto T., Hayashi N., Takehara T et al, 1999. Impaired allostimulatory capacity of peripheral blood dendric cells recovered from hepatitis C virus-infected
individuals. J Immunol; 162:55.pp.84-91
Нийтлэлийн нээгдсэн тоо: 431
